Mainstay Medical Announces US$125 Million Equity Financing Transaction

Contributed by: Business Wire

Logo

Tags

Health

Medical Devices

Neurology

Health Technology

Physical Therapy

Other Health

Biotechnology

Equity Financing Transaction

More Like This

The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire)

Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients

Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

ONWARD® Medical Obtains Debt Financing with up to €52.5 Million Secured Loan from Runway Growth Capital LLC

Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus Dysfunction